NASDAQ:VINC

Vincerx Pharma Competitors

$17.60
-0.70 (-3.83 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$17.48
Now: $17.60
$18.50
50-Day Range
$18.30
MA: $20.31
$25.90
52-Week Range
$9.35
Now: $17.60
$26.75
Volume68,236 shs
Average Volume96,599 shs
Market Capitalization$144.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Vincerx Pharma (NASDAQ:VINC) Vs. SGTX, IVA, GMTX, LABP, TERN, and SNSE

Should you be buying VINC stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Vincerx Pharma, including Sigilon Therapeutics (SGTX), Inventiva (IVA), Gemini Therapeutics (GMTX), Landos Biopharma (LABP), Terns Pharmaceuticals (TERN), and Sensei Biotherapeutics (SNSE).

Vincerx Pharma (NASDAQ:VINC) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vincerx Pharma and Sigilon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Sigilon Therapeutics01302.75

Sigilon Therapeutics has a consensus price target of $53.75, indicating a potential upside of 215.43%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Vincerx Pharma.

Valuation and Earnings

This table compares Vincerx Pharma and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Vincerx Pharma and Sigilon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
Sigilon TherapeuticsN/AN/AN/A

Summary

Sigilon Therapeutics beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Profitability

This table compares Vincerx Pharma and Inventiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
InventivaN/AN/AN/A

Earnings and Valuation

This table compares Vincerx Pharma and Inventiva's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
InventivaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Vincerx Pharma and Inventiva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Inventiva10402.60

Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 104.59%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Vincerx Pharma.

Summary

Inventiva beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Gemini Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
Gemini TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Vincerx Pharma and Gemini Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
Gemini TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Gemini Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Gemini Therapeutics00403.00

Gemini Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 95.73%. Given Gemini Therapeutics' higher possible upside, analysts clearly believe Gemini Therapeutics is more favorable than Vincerx Pharma.

Summary

Gemini Therapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
Landos BiopharmaN/AN/AN/A

Valuation & Earnings

This table compares Vincerx Pharma and Landos Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
Landos BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Landos Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Landos Biopharma01302.75

Landos Biopharma has a consensus price target of $25.50, suggesting a potential upside of 121.55%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Vincerx Pharma.

Summary

Landos Biopharma beats Vincerx Pharma on 2 of the 3 factors compared between the two stocks.

Vincerx Pharma (NASDAQ:VINC) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Vincerx Pharma and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/A

Valuation & Earnings

This table compares Vincerx Pharma and Terns Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
Terns PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Terns Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Terns Pharmaceuticals00303.00

Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 70.30%. Given Vincerx Pharma's higher possible upside, equities research analysts clearly believe Vincerx Pharma is more favorable than Terns Pharmaceuticals.

Vincerx Pharma (NASDAQ:VINC) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares Vincerx Pharma and Sensei Biotherapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/AN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Vincerx Pharma and Sensei Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vincerx Pharma00103.00
Sensei Biotherapeutics00403.00

Sensei Biotherapeutics has a consensus price target of $29.50, suggesting a potential upside of 108.92%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Vincerx Pharma.

Profitability

This table compares Vincerx Pharma and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vincerx PharmaN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/A

Summary

Sensei Biotherapeutics beats Vincerx Pharma on 2 of the 2 factors compared between the two stocks.


Vincerx Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SGTX
Sigilon Therapeutics
1.4$17.04-8.2%$536.64 millionN/A0.00Increase in Short Interest
Inventiva logo
IVA
Inventiva
1.4$13.34-0.5%$515.32 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.24-2.0%$483.31 millionN/A0.00Analyst Report
Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.51-2.1%$461.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.91-1.1%$449.99 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.12-5.8%$431.90 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74-12.1%$426.49 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.07-5.6%$414.84 millionN/A0.00
PRTG
Portage Biotech
0.0$26.99-7.6%$326.12 millionN/A0.00High Trading Volume
News Coverage
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.34-4.1%$292.09 millionN/A-2.84
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.50-16.2%$276.04 millionN/A-2.57Unusual Options Activity
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.89-8.7%$246.28 millionN/A0.00
LBPH
Longboard Pharmaceuticals
1.9$11.63-7.0%$196.75 millionN/A0.00Analyst Report
Quiet Period Expiration
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.10-3.4%$193.10 millionN/A0.00Increase in Short Interest
GANX
Gain Therapeutics
1.7$14.50-2.8%$164.30 millionN/A0.00Analyst Revision
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55-0.1%$149.71 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52-18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52-9.5%$123.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.87-6.5%$84.17 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$14.76-2.8%$57.68 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24-3.4%$52.67 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.58-1.1%$46.48 millionN/A0.00News Coverage
Gap Down
VIRX
Viracta Therapeutics
1.7$8.00-0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65-0.3%$40.18 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20-6.3%$37.69 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.55-2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36-3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26-23.2%$12.65 millionN/A0.00Gap Up
BCTX
BriaCell Therapeutics
0.0$3.26-0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57-4.7%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.07-0.0%$0.00N/A0.00Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00News Coverage
BMEA
Biomea Fusion
0.0N/AN/A$0.00N/A0.00Upcoming Earnings
High Trading Volume
RXRX
Recursion Pharmaceuticals
0.0N/AN/A$0.00N/A0.00Upcoming Earnings
High Trading Volume
RPHM
Reneo Pharmaceuticals
0.3$13.00-2.4%$0.00N/A0.00Insider Buying
News Coverage
Gap Down
SCPS
Scopus BioPharma
1.4$7.54-3.3%$0.00N/A0.00Increase in Short Interest
Gap Down
VECT
VectivBio
0.0$16.12-1.8%$0.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.